History & Milestones

Translating the vision of synergistic combination pharmaceuticals into important new medicines:

2000	CombinatoRx founded based on the then theoretical idea that selective action through synergy between two drugs could create fundamentally better medicines. Invented and built working prototype of combination High Throughput Screening (cHTS™) drug discovery technology.
2005	Collaborations Collaboration with Angiotech Pharmaceuticals, Inc. to discover and develop compounds for use in medical devices and other interventional medicine products Collaborated with Cure Huntington's Disease Initiative (CHDI) to discover and develop drug candidates that may prevent or slow progression of Huntington's disease
2006	Positive Human Clinical Trials CRx-102 - Positive clinical results (hand osteoarthritis and rheumatoid arthritis) CRx-170 - Positive clinical results (asthma) Collaborations Joined forces with Cystic Fibrosis Foundation Therapeutics (CFFT) to develop novel cystic fibrosis therapeutics Collaborated with Fovea Pharmaceuticals SA to develop synergistic combination formulations to treat ophthalmic diseases
2007	Clinical Initiated Phase 2b clinical trials for CRx-102 in osteoarthritis and rheumatoid arthritis Initiated Phase 2a clinical trials for CRx-401 in Type 2 Diabetes Initiated Phase 2a clinical trials for CRx-191 in psoriasis Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077 Neuromed Initiates Pivotal Phase 3 Clinical Trial of NMED-1077 in Chronic Low Back Pain Collaborations Neuromed acquired the U.S. licensing rights to Exalgo, a Phase 3 once-daily form of hydromorphone commonly known by its brand name Dilaudid (Abbott), a widely used opioids, from ALZA Corporation.
2008	Clinical Completed Phase 2a clinical trials for CRx-191 in psoriasis Completed Phase 2b clinical trials for CRx-102 in knee OA Completed Phase 2a clinical trials for CRx-401 in type 2 diabetes Completed Phase 2a clinical trials for CRx-197 in psoriasis Neuromed Completes Enrollment for Phase 3 Chronic Low Back Pain Clinical Trial of NMED-1077
2009	Clinical Neuromed Announces Exalgo (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial Neuromed submits the Complete Response for Exalgo to the FDA FDA Advisory Committee reviewed the Exalgo REMS program as proposed by Covidien and Neuromed. Collaborations Collaboration with Novartis focused on the discovery of novel anti-cancer combinations. Collaboration with PGxHealth LLC relating to the potential development of ATL313, and adenosine A2A receptor agonist, as a combination therapy for the treatment of multiple myeloma or other b-cell malignances. Neuromed Announces Sale of U.S. Rights to Drug Candidate Exalgo™(hydromorphone HCl) Extended-Release Tablets (CII) CombinatoRx and Neuromed Sign Merger Agreement.